Innate Pharma S.A.
IPHYF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $12,621 | $61,641 | $49,639 | $12,112 |
| % Growth | -79.5% | 24.2% | 309.8% | – |
| Cost of Goods Sold | $0 | $56,022 | $51,663 | $47,004 |
| Gross Profit | $12,621 | $5,619 | $6,011 | -$22,301 |
| % Margin | 100% | 9.1% | 12.1% | -184.1% |
| R&D Expenses | $51,980 | $56,022 | $51,663 | $47,004 |
| G&A Expenses | $11,933 | $17,972 | $14,473 | $15,991 |
| SG&A Expenses | $11,933 | $18,288 | $14,473 | $25,524 |
| Sales & Mktg Exp. | $0 | $316 | $0 | $9,533 |
| Other Operating Expenses | $283 | -$56,022 | -$2,700 | -$47,004 |
| Operating Expenses | $64,196 | $18,288 | $63,436 | $25,524 |
| Operating Income | -$51,575 | -$12,669 | -$57,425 | -$47,825 |
| % Margin | -408.6% | -20.6% | -115.7% | -394.9% |
| Other Income/Exp. Net | $2,104 | $5,099 | -$547 | $2,347 |
| Pre-Tax Income | -$49,471 | -$7,570 | -$57,972 | -$45,478 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$49,471 | -$7,570 | -$58,103 | -$52,809 |
| % Margin | -392% | -12.3% | -117.1% | -436% |
| EPS | -0.61 | -0.09 | -0.73 | -0.57 |
| % Growth | -577.8% | 87.7% | -28.1% | – |
| EPS Diluted | -0.61 | -0.09 | -0.73 | -0.57 |
| Weighted Avg Shares Out | 81,052 | 84,111 | 79,593 | 79,543 |
| Weighted Avg Shares Out Dil | 81,052 | 84,111 | 79,640 | 79,543 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,437 | $3,177 | $546 | $327 |
| Interest Expense | $566 | $640 | $288 | $312 |
| Depreciation & Amortization | $1,994 | $5,091 | $45,405 | $4,596 |
| EBITDA | -$46,911 | -$7,578 | -$12,279 | -$43,229 |
| % Margin | -371.7% | -12.3% | -24.7% | -356.9% |